Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Sumida-ku, Japan Clinical Trials

A listing of Sumida-ku, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (369) clinical trials

A Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy

The drug being tested in this study is called TAK-925. TAK-925 is being tested in healthy participants and patients with narcolepsy. This study will look at the safety, tolerability, pharmacokinetics, and efficacy of TAK-925. This study will consist of three parts. Part A will be a randomized, double-blind, placebo-controlled, multiple ...

Phase

0.0 miles

Learn More »

Survey Study for Velaglucerase Alfa (VPRIV) in Japan

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.

Phase N/A

0.29 miles

Learn More »

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug and how it affects blood ...

Phase

0.53 miles

Learn More »

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 1060 subjects will be ...

Phase

0.92 miles

Learn More »

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history) associated with the safety and effectiveness of evolocumab therapy for the patients with ...

Phase N/A

1.25 miles

Learn More »

SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.

Phase N/A

1.46 miles

Learn More »

SPYRAL HTN-ON MED Study

The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.

Phase N/A

1.46 miles

Learn More »

Functional Assessment by Virtual Online Reconstruction. The FAVOR III Europe Japan Study

Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography (CAG). Lesions are often quantified by visual assessment of the angiogram, but physiological assessment of the functional significance by fractional flow reserve has been shown to improve clinical outcome, to reduce number ...

Phase N/A

1.46 miles

Learn More »

Rainbow Extension Study

The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301

Phase

1.46 miles

Learn More »

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.

Phase

1.49 miles

Learn More »